REGN — Regeneron Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $66.35bn
- $60.31bn
- $14.34bn
Regeneron Pharma gains as BofA upgrades rating
U.S. STOCKS ON THE MOVE-United Airlines Holdings, Energy companies, Tesla
U.S. STOCKS ON THE MOVE-Shake Shack, Arrowhead Pharmaceuticals, Lockheed Martin
U.S. STOCKS ON THE MOVE-Alkermes, Ball Corp, NovaBridge
Citi sees momentum in US pharma and biotech into 2026, updates ratings on top picks
Johnson & Johnson halts mid-stage trial of experimental eczema drug (updated)
Brief: Sanofi And Regeneron's Dupixent Approved In Japan For Children With Bronchial Asthma
Several top drugmakers to lower US prices for some drugs, sources say (updated)
Several top drugmakers to lower US prices for some drugs-sources
AbbVie, several other pharma companies near MFN deal with Trump, sources say (updated)
US FDA approves GSK's twice-yearly asthma drug (updated)
US FDA approves GSK's twice-yearly asthma drug
Brief: EMA's CHMP Recommended Granting Marketing Authorisation For Moderna's Mnexspike
US FDA brass pushed internally for speedier Lilly weight-loss pill verdict
Biohaven jumps as cancer treatment shows promise in early-stage trial
Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial
Ocular jumps on plans to fast-track FDA filing for eye disease drug
Ocular Therapeutix rises on plans to fast-track FDA filing for eye disease drug
Brief: Regeneron Pharmaceuticals Says Lynozyfic Monotherapy In Newly Diagnosed Multiple Myeloma Shows Impressive Responses